CliffBio
small molecule

KEVEYIS

DICHLORPHENAMIDE

Loss of exclusivity—loss of exclusivity
CompanyXeris Pharmaceuticals →See this company's full patent-cliff portfolio

Drug detail

Brand nameKEVEYIS
Active ingredientDICHLORPHENAMIDE
Strength50MG
Dosage formTABLET
RouteORAL
ModalitySmall molecule
FDA approvalAugust 2015
Marketing statusRX

More from Xeris Pharmaceuticals

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.

KEVEYIS patent cliff — loss of exclusivity — | CliffBio